RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

NCT05979740 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Muscle Invasive Bladder Cancer
HER2 Expression
Radiotherapy
PD-1
Antibody-drug Conjugates

Interventions

DRUG: Disitamab Vedotin and Toripalimab

Sponsor

RenJi Hospital